Literature DB >> 20456487

Hepcidin treatment in Hfe-/- mice diminishes plasma iron without affecting erythropoiesis.

María-Josefa Morán-Jiménez1, Manuel Méndez, Begoña Santiago, María-Elena Rodríguez-García, María-Isabel Moreno-Carralero, Ana-Cristina Sánchez-Lucío, Montserrat Grau, Rafael Enríquez-de-Salamanca.   

Abstract

BACKGROUND: Iron is essential for mammalian metabolism and its cellular concentration is controlled by regulating its acquisition and storage. Haemochromatosis is a condition involving iron overload that is characterised by increased duodenal iron absorption and a progressive accumulation of iron in vital organs. Hepcidin is the main hormone that regulates iron homoestasis and it is secreted by the liver.
MATERIALS AND METHODS: We have studied how extended hepcidin administration affects the iron load status, plasma and tissue iron concentration, erythropoiesis and the expression of proteins involved on iron homeostasis in haemochromatotic (Hfe(-/-)) and wild-type mice.
RESULTS: Hepcidin reverted the high plasma iron concentrations in Hfe(-/-) mice to normal values. The high concentration of hepatic iron was not altered in the liver of these Hfe(-/-) mice. Hepcidin administration did not disturb erythropoiesis in either Hfe(-/-) or wild-type mice and likewise, hepcidin did not modify the expression of any protein analysed in the liver, duodenum or spleen of Hfe(-/-) and wild-type mice. These data confirm that hepcidin administration diminishes plasma iron concentrations.
CONCLUSION: Treatment with sustained doses of hepcidin diminishes plasma iron concentrations in Hfe(-/-) mice.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20456487     DOI: 10.1111/j.1365-2362.2010.02291.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  10 in total

1.  A tincture of hepcidin cures all: the potential for hepcidin therapeutics.

Authors:  Thomas B Bartnikas; Mark D Fleming
Journal:  J Clin Invest       Date:  2010-11-22       Impact factor: 14.808

2.  17β-Estradiol inhibits iron hormone hepcidin through an estrogen responsive element half-site.

Authors:  Qing Yang; Jinlong Jian; Stuart Katz; Steven B Abramson; Xi Huang
Journal:  Endocrinology       Date:  2012-04-25       Impact factor: 4.736

3.  Reducing iron accumulation: A potential approach for the prevention and treatment of postmenopausal osteoporosis.

Authors:  Bin Chen; Guang-Fei Li; Ying Shen; X I Huang; You-Jia Xu
Journal:  Exp Ther Med       Date:  2015-05-08       Impact factor: 2.447

4.  Striking the target in iron overload disorders.

Authors:  Karin E Finberg
Journal:  J Clin Invest       Date:  2013-03-25       Impact factor: 14.808

5.  BMP6 treatment compensates for the molecular defect and ameliorates hemochromatosis in Hfe knockout mice.

Authors:  Elena Corradini; Paul J Schmidt; Delphine Meynard; Cinzia Garuti; Giuliana Montosi; Shanzhuo Chen; Slobodan Vukicevic; Antonello Pietrangelo; Herbert Y Lin; Jodie L Babitt
Journal:  Gastroenterology       Date:  2010-08-01       Impact factor: 22.682

6.  Tmprss6 is a genetic modifier of the Hfe-hemochromatosis phenotype in mice.

Authors:  Karin E Finberg; Rebecca L Whittlesey; Nancy C Andrews
Journal:  Blood       Date:  2011-02-25       Impact factor: 22.113

Review 7.  HFE-related hemochromatosis: an update for the rheumatologist.

Authors:  Emma Husar-Memmer; Andreas Stadlmayr; Christian Datz; Jochen Zwerina
Journal:  Curr Rheumatol Rep       Date:  2014-01       Impact factor: 4.592

Review 8.  Hepcidin: A Promising Therapeutic Target for Iron Disorders: A Systematic Review.

Authors:  Jing Liu; Bingbing Sun; Huijun Yin; Sijin Liu
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

Review 9.  Molecular basis of HFE-hemochromatosis.

Authors:  Maja Vujić
Journal:  Front Pharmacol       Date:  2014-03-11       Impact factor: 5.810

10.  A computational model to understand mouse iron physiology and disease.

Authors:  Jignesh H Parmar; Pedro Mendes
Journal:  PLoS Comput Biol       Date:  2019-01-04       Impact factor: 4.475

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.